Dr. Chaft on the Next Steps of Osimertinib Research in EGFR+ NSCLC

Video

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps of osimertinib research in EGFR-mutant non–small cell lung cancer.

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps of osimertinib (Tagrisso) research in EGFR-mutant non–small cell lung cancer (NSCLC).

Despite the short follow-up, results from the phase 3 ADAURA trial were impressive and garnered both discussion and debate after the 2020 ASCO Virtual Scientific Program. The hazard ratio of 0.17 for disease recurrence or death, which was reported in patients with stage II to IIIA disease who received adjuvant osimertinib, was a major breakthrough in the lung cancer space, Chaft says. Moreover, adjuvant osimertinib demonstrated a statistically significant improvement in disease-free survival in patients with stage IB to IIIA EGFR-mutant NSCLC.

However, there were also a few surprising findings from this trial, such as the high number of recurrences that were reported in the control arm.

In the short term, additional findings are expected, such as recurrence patterns and updates on quality of life. In the long term, the field will await recurrence rates after treatment discontinuation. Since this is currently unknown, many are hesitant to administer this agent, Chaft concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD